


Name of Policy: Administration of Radionuclides Policy Number: 3364-106-N02 Approving Officer: Chief Operating Officer Responsible Agent: Director of Cardiovascular Services, Medical Director, Non-Invasive Cardiac Imaging Scope: University of Toledo Medical Center		 Effective date: 3/24/2025 Original effective date: 7/1990	
Key words: Radiation, Nuclear Testing, Stress Test, Administration, Radiopharmaceuticals			
<input type="checkbox"/>	New policy proposal	<input type="checkbox"/>	Minor/technical revision of existing policy
<input type="checkbox"/>	Major revision of existing policy	<input checked="" type="checkbox"/>	Reaffirmation of existing policy

(A) Policy Statement

The Licensed, Registered Nuclear Medicine Technologist will inject all Radiopharmaceuticals. Prior to injection, the technologist will check the dose in the dose calibrator and record the amount of activity. Verify that there is a written order by a physician for the specific procedure, verify that there is a proper diagnosis for the procedure and verify the identification of the patient. Verify pregnancy or breast-feeding status. Explain the procedure to the patient, the patient’s family, or guardian and ensure NP has obtained signed consent to perform the procedure.

(B) Purpose of Policy

The policy establishes the authorization and proper procedure to administer Radiopharmaceuticals at UTMC.

(C) Procedure

1. Verify that there is a physician’s written order, verify that the proper procedure has been ordered for the patient’s diagnosis, verify pregnancy or breast-feeding status, and verify the patient’s identification with the patient requisition form. Confirm the patient’s identity using two patient identifiers. Verify the patient’s name, birth date, and medical record number against the test requisition form and for inpatients, against their hospital I.D. band. This ensures that the correct procedure is performed on the correct patient, thus eliminating unnecessary radiation exposure to patients and personnel.
2. Explain the procedure to the patient, patient’s family, and /or guardian and ensure NP has obtained a signed consent. If the patient is unable to be educated and there are no family members or guardians available, then the reason should be recorded on the worksheet. This provides the patient the opportunity to refuse the procedure if they so choose. The ordering physician should be notified as soon as possible if the patient refuses the procedure. Female patients who are pregnant or who think they may be pregnant will be informed of the radiation risk to the fetus and the procedure will not be performed until the ordering physician is notified. Both the patient and the physician must give approval for the procedure to be performed. Patients who are breastfeeding will be instructed to stop and will be given a date as to when they can resume breastfeeding.
3. A physician should be available in the event treatment is needed for an adverse reaction or incident, although this is a highly infrequent occurrence. Emergency medication and equipment are available on “code carts” located in the Heart and Vascular Center.
4. All Radiopharmaceuticals are delivered as sealed UNIT DOSES.

3364-106-N02 Administration of Radionuclides

5. All nuclear injections are performed using radiation safety precautions. Syringe shields must be used and protective clothing (lab coats, gloves) must be worn. Universal precautions and sterile techniques must be followed.
6. Using a lead glass shield, the Nuclear Technologist will verify radiopharmaceutical identity, route of administration, and expiration date and time. No dose will be administered after its expiration time.
7. Check the Radiopharmaceutical in a dose calibrator to ensure that the Radiopharmaceutical dose activity is within the dose guideline range of the approved amount for the procedure.
8. In the unlikely case of a pediatric patient, the RSO or physicist and radiopharmacy will verify appropriate dose based on weight.
9. All radiopharmaceutical injections will be performed in designated areas.
10. All Radiopharmaceuticals are injected intravenously using radiation safety precautions (syringe shields). If performing a straight intravenous injection, replace the needle with a fresh sterile needle.
11. The exact dose amount assayed in the dose calibrator will be recorded along with the patient's name, procedure type, identity of the radiopharmaceutical, expiration date and time, route of administration, injection site, date and time of injection, and initials of administering nuclear medicine technologist, into the appropriate dose log or computer file.
12. If a misadministration occurs as described in the Heart and Vascular Center policy "Radiopharmaceutical Recordable Event," then the reporting requirements of that policy is to be followed.

<p>Approved by:</p> <p>/s/</p> <hr/> <p>Todd Korzec, RN, BSN Director, Cardiovascular Services</p> <p>1/31/2025</p> <hr/> <p>Date</p> <p>/s/</p> <hr/> <p>Samer Khouri, MD Medical Director, Non-Invasive Cardiac Imaging</p> <p>3/7/2025</p> <hr/> <p>Date</p> <p>/s/</p> <hr/> <p>Christine Stesney-Ridenour, FACHE Chief Operating Officer</p> <p>3/24/2025</p> <hr/> <p>Date</p> <p><i>Review/Revision Completed by:</i> <i>Director, Cardiovascular Services</i></p>	<p>Policies Superseded by This Policy:</p> <ul style="list-style-type: none">• <i>None</i> <p>Initial effective date: 7/1990</p> <p>Review/Revision Date:</p> <p>2/93 4/93 12/95 7/97 8/99 7/01 5/04 7/07 8/10 6/13 3/16 3/19 2/22 3/24/2025</p> <p>Next review date: 3/24/2028</p>
---	--